TNFRSF17 and Miyoshi myopathy: The most widely studied MM CAR-T-cell target is BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF17) whose preferential expression in plasma cells rather than hematopoietic stem cells makes it an ideal antigen target.40 In March 2021 and February 2022, the FDA approved 2 anti-BCMA CAR-T-cell products for MM treatment: ide-cel/Abecma and cilta-cel.